Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Ev3’s Atherectomy Business On The Upswing After Troubled First Quarter

This article was originally published in The Gray Sheet

  • News

Executive Summary

Endovascular device firm ev3's formerly rocky marriage with FoxHollow is now on steadier ground with a better-than-expected recovery of its atherectomy business in the second quarter

You may also be interested in...



Ev3 Atherectomy Biz Stabilizing After Sales Force Improvements, Firm Says

Ev3 believes a sales force restructuring initiated earlier this year is bearing fruit for its struggling atherectomy business

Ev3 Atherectomy Biz Stabilizing After Sales Force Improvements, Firm Says

Ev3 believes a sales force restructuring initiated earlier this year is bearing fruit for its struggling atherectomy business

ev3 Expands Neurovascular Division With Acquisition Of Chestnut

ev3 is expanding its neurovascular division, already the fastest-growing segment of the company, by buying Chestnut Medical Technologies for $75 million up-front and up to $75 million in milestone payments, the companies announced June 2

Table

View full table

Tags:
Latest Headlines

NWW: Studies Back Nevro Pain Treatment, FTC Blesses Resonetics Nitinol Deal, Genetic Test Identifies Best RDN Patients

Getting Personal With Tom Miller: CEO Turned VC On Ethical Bets In Diagnostics

Postmarket Surveillance Continues To Challenge AI/ML Device Regulators

Q&A: Allyson Mullen On ‘Uncharted Waters’ Of Breakthrough Pathway

See All
UsernamePublicRestriction

Register

MT026409

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By